OUR PIPELINE

Voruciclib is an orally administered CDK9 inhibitor. Inhibition of CDK9 blocks the production of MCL1, an established resistance mechanism to the BCL2 inhibitor venetoclax. CDK9 also inhibits MYC, a transcription factor regulating cell proliferation and growth that has also been implicated in KRAS mutant tumors. This Phase 1b trial is evaluating voruciclib dose and schedule in patients with acute myeloid leukemia and B-cell malignancies.

We are evaluating the dose and schedule of voruciclib as a single-agent and in combination venetoclax, initially in patients with AML and subsequently across multiple indications.

Enrollment Status
AML: Ongoing
B-Cell Malignancies: Ongoing

ME-344 is a novel tumor selective mitochondrial inhibitor drug candidate that has been investigated clinically in patients with solid tumors. Data was reported at ASCO 2019 from an investigator-initiated, multi-center, randomized study of ME-344 in combination with placebo or the VEGF inhibitor bevacizumab (marketed as Avastin®). The data demonstrated that ME-344 in combination with bevacizumab was biologically active in HER2 negative breast cancer patients consistent with decreased cancer proliferation. MEI is planning to initiate a Phase 1b clinical study evaluating ME-344 with bevacizumab or other anti-angiogenic agent in patients with select solid tumors.

Enrollment Status
Study Complete